{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T12:11:42Z","timestamp":1794485502383,"version":"4.9.1"},"reference-count":59,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","award":["CAAA617A1US11T"],"award-info":[{"award-number":["CAAA617A1US11T"]}],"id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","award":["PF-23-1153194-01-CDP"],"award-info":[{"award-number":["PF-23-1153194-01-CDP"]}],"id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society Inc","doi-asserted-by":"publisher","award":["IRG-21-049-61-IRG"],"award-info":[{"award-number":["IRG-21-049-61-IRG"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013187","name":"Randy Shaver Cancer Research and Community Fund","doi-asserted-by":"publisher","award":["R50CA211256"],"award-info":[{"award-number":["R50CA211256"]}],"id":[{"id":"10.13039\/100013187","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-22-2-0025"],"award-info":[{"award-number":["W81XWH-22-2-0025"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-22-1-0242"],"award-info":[{"award-number":["W81XWH-22-1-0242"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","award":["HT9425-25-1-0438"],"award-info":[{"award-number":["HT9425-25-1-0438"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UM1TR004405"],"award-info":[{"award-number":["UM1TR004405"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011539","name":"University of Minnesota Masonic Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011539","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["ECCS-2025124"],"award-info":[{"award-number":["ECCS-2025124"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007316","name":"National Cancer Institute Division of Cancer Prevention","doi-asserted-by":"publisher","award":["R37 1R37CA288972-01"],"award-info":[{"award-number":["R37 1R37CA288972-01"]}],"id":[{"id":"10.13039\/100007316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007316","name":"National Cancer Institute Division of Cancer Prevention","doi-asserted-by":"publisher","award":["R01CA270539"],"award-info":[{"award-number":["R01CA270539"]}],"id":[{"id":"10.13039\/100007316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007316","name":"National Cancer Institute Division of Cancer Prevention","doi-asserted-by":"publisher","award":["R01CA174777"],"award-info":[{"award-number":["R01CA174777"]}],"id":[{"id":"10.13039\/100007316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007249","name":"University of Minnesota","doi-asserted-by":"publisher","award":["STTR R41CA268344-01"],"award-info":[{"award-number":["STTR R41CA268344-01"]}],"id":[{"id":"10.13039\/100007249","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007249","name":"University of Minnesota","doi-asserted-by":"publisher","award":["P30CA077598"],"award-info":[{"award-number":["P30CA077598"]}],"id":[{"id":"10.13039\/100007249","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.xcrm.2026.102764","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T15:11:16Z","timestamp":1776697876000},"page":"102764","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Plasma extracellular vesicle proteomics nominates candidate biomarkers of 177Lu-PSMA-617 outcomes in metastatic prostate cancer patients"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0460-3039","authenticated-orcid":false,"given":"Ali T.","family":"Arafa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ella","family":"Boytim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan L.","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lily","family":"Kollitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianzhong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen M.","family":"Storey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Bloom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Jha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Okazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles J.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas A.","family":"Zorko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Steinberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzan","family":"Cayci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingchun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter W.","family":"Villalta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott M.","family":"Dehm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin H.","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin M.","family":"Drake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel S.","family":"Antonarakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2026.102764_bib1","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(24)01919-6","article-title":"177Lu-PSMA-617 for metastatic prostate cancer: aiming for the right spot","volume":"404","author":"Mateo","year":"2024","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.xcrm.2026.102764_bib2","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.2967\/jnumed.115.171397","article-title":"PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617","volume":"57","author":"Kratochwil","year":"2016","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.xcrm.2026.102764_bib3","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.102764_bib4","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.xcrm.2026.102764_bib5","unstructured":"Novartis Pluvicto\u2122 Demonstrates Statistically Significant and Clinically Meaningful rPFS Benefit in Patients with PSMA-Positive Metastatic Hormone-Sensitive Prostate Cancer. (2025)."},{"key":"10.1016\/j.xcrm.2026.102764_bib6","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.2967\/jnumed.124.267816","article-title":"Efficacy and Toxicity of [177Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data","volume":"65","author":"Murthy","year":"2024","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.xcrm.2026.102764_bib7","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1200\/JCO.2025.43.16_suppl.5011","article-title":"Predictive and prognostic value of baseline PSMA-PET total tumor volume and SUV mean within ENZA-p, a randomized phase II trial of enzalutamide versus enzalutamide plus [ 177 Lu] Lu-PSMA-617 (ANZUP1901)","volume":"43","author":"Emmett","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102764_bib8","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1200\/JCO.2025.43.5_suppl.190","article-title":"Serum biomarkers in metastatic castration-resistant prostate cancer (mCRPC) patients receiving [ 177 Lu]Lu-PSMA-617 therapy: Post hoc analysis of a phase II clinical trial","volume":"43","author":"Giunta","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102764_bib9","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.2967\/jnumed.124.267723","article-title":"Initial Experience with [177Lu]Lu-PSMA-617 After Regulatory Approval for Metastatic Castration-Resistant Prostate Cancer: Efficacy, Safety, and Outcome Prediction","volume":"65","author":"Gafita","year":"2024","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.xcrm.2026.102764_bib10","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1200\/JCO.22.00644","article-title":"Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials","volume":"40","author":"Deek","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102764_bib11","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1200\/JCO.23.00573","article-title":"Prostate-Specific Membrane Antigen-Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225Ac-J591","volume":"42","author":"Tagawa","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102764_bib12","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1038\/s41591-023-02284-w","article-title":"Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial","volume":"29","author":"Shenderov","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102764_bib13","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.annonc.2021.03.005","article-title":"Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I\/II IMMU-132-01 basket trial","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.102764_bib14","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1158\/2159-8290.CD-23-0964","article-title":"Xaluritamig, a STEAP1 \u00d7 CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study","volume":"14","author":"Kelly","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2026.102764_bib15","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12128","article-title":"Molecular evaluation of five different isolation methods for extracellular vesicles reveals different clinical applicability and subcellular origin","volume":"10","author":"Veerman","year":"2021","journal-title":"J. Extracell. Vesicles"},{"key":"10.1016\/j.xcrm.2026.102764_bib16","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/s41389-022-00431-5","article-title":"Exosomes and cancer - Diagnostic and prognostic biomarkers and therapeutic vehicle","volume":"11","author":"Wang","year":"2022","journal-title":"Oncogenesis"},{"key":"10.1016\/j.xcrm.2026.102764_bib17","doi-asserted-by":"crossref","DOI":"10.3402\/jev.v4.27066","article-title":"Biological properties of extracellular vesicles and their physiological functions","volume":"4","author":"Y\u00e1\u00f1ez-M\u00f3","year":"2015","journal-title":"J. Extracell. Vesicles"},{"key":"10.1016\/j.xcrm.2026.102764_bib18","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.ccell.2024.06.003","article-title":"Circulating tumor extracellular vesicles to monitor metastatic prostate cancer genomics and transcriptomic evolution","volume":"42","author":"Casanova-Salas","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2026.102764_bib19","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.3390\/cancers16244261","article-title":"Isolation of Plasma Extracellular Vesicles for High-Depth Analysis of Proteomic Biomarkers in Metastatic Castration-Resistant Prostate Cancer Patients","volume":"16","author":"Arafa","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.xcrm.2026.102764_bib20","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1158\/1078-0432.CCR-24-3027","article-title":"PSMA+ Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts","volume":"31","author":"Andrews","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102764_bib21","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ddtec.2021.06.006","article-title":"Data-independent acquisition (DIA): An emerging proteomics technology for analysis of drug-metabolizing enzymes and transporters","volume":"39","author":"Li","year":"2021","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.xcrm.2026.102764_bib22","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1002\/mas.21781","article-title":"Advances in data-independent acquisition mass spectrometry towards comprehensive digital proteome landscape","volume":"42","author":"Kitata","year":"2023","journal-title":"Mass Spectrom. Rev."},{"key":"10.1016\/j.xcrm.2026.102764_bib23","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1158\/2159-8290.CD-24-1509","article-title":"High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes","volume":"15","author":"Sharifi","year":"2025","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2026.102764_bib24","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1158\/1078-0432.CCR-22-3233","article-title":"PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer","volume":"29","author":"Gupta","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102764_bib25","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1200\/JCO.18.01731","article-title":"Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study","volume":"37","author":"Armstrong","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102764_bib26","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.102764_bib27","article-title":"Circulating tumor cell detection in cancer patients using in-flow deep learning holography","author":"Mallery","year":"2025","journal-title":"arXiv"},{"key":"10.1016\/j.xcrm.2026.102764_bib28","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(22)00605-2","article-title":"PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial","volume":"23","author":"Buteau","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2026.102764_bib29","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s41824-023-00165-6","article-title":"Quantitative assessment of PSMA PET response to therapy in castration-sensitive prostate cancer using an automated imaging platform for disease identification and measurement","volume":"7","author":"Duriseti","year":"2023","journal-title":"Eur. J. Hybrid Imaging"},{"key":"10.1016\/j.xcrm.2026.102764_bib30","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.eururo.2025.07.011","article-title":"Pathogenic Genomic Alterations in Circulating Tumor DNA Predict Overall Survival in Men with Metastatic Castrate-resistant Prostate Cancer","volume":"89","author":"Halabi","year":"2026","journal-title":"Eur. Urol."},{"key":"10.1016\/j.xcrm.2026.102764_bib31","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1200\/JCO.2013.52.3696","article-title":"Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer","volume":"32","author":"Halabi","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102764_bib32","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/annonc\/mdv594","article-title":"A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel","volume":"27","author":"Chi","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.102764_bib33","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S1470-2045(21)00274-6","article-title":"Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study","volume":"22","author":"Gafita","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2026.102764_bib34","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1186\/1471-2407-14-461","article-title":"KIF2A silencing inhibits the proliferation and migration of breast cancer cells and correlates with unfavorable prognosis in breast cancer","volume":"14","author":"Wang","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.xcrm.2026.102764_bib35","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1038\/s41467-021-23241-6","article-title":"INPP4B promotes PI3K\u03b1-dependent late endosome formation and Wnt\/\u03b2-catenin signaling in breast cancer","volume":"12","author":"Rodgers","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.102764_bib36","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s42003-023-04795-1","article-title":"ALAN is a computational approach that interprets genomic findings in the context of tumor ecosystems","volume":"6","author":"Bergom","year":"2023","journal-title":"Commun. Biol."},{"key":"10.1016\/j.xcrm.2026.102764_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/677fdf34-651e-4dc8-a0be-d0d633237a85","article-title":"A-methylacyl-CoA racemase (AMACR) and prostate-cancer risk: a meta-analysis of 4,385 participants","volume":"8","author":"Jiang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.xcrm.2026.102764_bib38","first-page":"89","article-title":"Spliceosome component SF3B1 as novel prognostic biomarker and therapeutic target for prostate cancer","volume":"212","author":"Jim\u00e9nez-Vacas","year":"2019","journal-title":"Transl. Res. J. Lab. Clin. Med."},{"key":"10.1016\/j.xcrm.2026.102764_bib39","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1186\/s12967-024-05658-x","article-title":"Effect of the mRNA decapping enzyme scavenger (DCPS) inhibitor RG3039 on glioblastoma","volume":"22","author":"Duan","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.xcrm.2026.102764_bib40","article-title":"Emerging role and clinical implication of mRNA scavenger decapping enzyme in colorectal cancer","volume":"253","author":"Shamoun","year":"2024","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.xcrm.2026.102764_bib41","doi-asserted-by":"crossref","first-page":"4248","DOI":"10.1038\/s44319-025-00520-7","article-title":"Uridine phosphorylase-1 supports metastasis by altering immune and extracellular matrix landscapes","volume":"26","author":"Whyte","year":"2025","journal-title":"EMBO Rep."},{"key":"10.1016\/j.xcrm.2026.102764_bib42","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1007\/s00261-020-02745-7","article-title":"Semi-automatic evaluation of baseline whole-body tumor burden as an imaging biomarker of 68Ga-PSMA-11 PET\/CT in newly diagnosed prostate cancer","volume":"45","author":"Zou","year":"2020","journal-title":"Abdom. Radiol."},{"key":"10.1016\/j.xcrm.2026.102764_bib43","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf207","article-title":"Clinical Response to Novel Combination of Trastuzumab Deruxtecan and Abiraterone in HER2-Expressing Metastatic Castration-Resistant Prostate Cancer","volume":"30","author":"Rajendran","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.xcrm.2026.102764_bib44","doi-asserted-by":"crossref","first-page":"5010","DOI":"10.1200\/JCO.2025.43.16_suppl.5010","article-title":"First-in-human results of terbium-161[ 161 Tb]Tb-PSMA-I&T radioligand treatment in patients with metastatic castration-resistant prostate cancer (VIOLET): A single-centre, single-arm, phase I\/II study","volume":"43","author":"Buteau","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102764_bib45","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/nrc3342","article-title":"The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance","volume":"12","author":"Bouwman","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2026.102764_bib46","first-page":"121","article-title":"p21\/p53, cellular growth control and genomic integrity","volume":"227","author":"el-Deiry","year":"1998","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.xcrm.2026.102764_bib47","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc2401","article-title":"Tailoring to RB: tumour suppressor status and therapeutic response","volume":"8","author":"Knudsen","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2026.102764_bib48","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/0955300021000038653","article-title":"Single-hit mechanism of tumour cell killing by radiation","volume":"79","author":"Chapman","year":"2003","journal-title":"Int. J. Radiat. Biol."},{"key":"10.1016\/j.xcrm.2026.102764_bib49","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.ijrobp.2004.03.005","article-title":"Role of cell cycle in mediating sensitivity to radiotherapy","volume":"59","author":"Pawlik","year":"2004","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.xcrm.2026.102764_bib50","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature14664","article-title":"Comprehensive genomic profiles of small cell lung cancer","volume":"524","author":"George","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.102764_bib51","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nm.4045","article-title":"Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer","volume":"22","author":"Beltran","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102764_bib52","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41592-019-0638-x","article-title":"DIA-NN: neural networks and interference correction enable deep proteome coverage in high throughput","volume":"17","author":"Demichev","year":"2020","journal-title":"Nat. Methods"},{"key":"10.1016\/j.xcrm.2026.102764_bib53","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1158\/1541-7786.MCR-23-0976","article-title":"Unraveling the Global Proteome and Phosphoproteome of Prostate Cancer Patient-Derived Xenografts","volume":"22","author":"Sychev","year":"2024","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102764_bib54","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.ccell.2019.02.005","article-title":"The Proteogenomic Landscape of Curable Prostate Cancer","volume":"35","author":"Sinha","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2026.102764_bib55","doi-asserted-by":"crossref","first-page":"5433","DOI":"10.1158\/1078-0432.CCR-18-1229","article-title":"The Proteome of Prostate Cancer Bone Metastasis Reveals Heterogeneity with Prognostic Implications","volume":"24","author":"Iglesias-Gato","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102764_bib56","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.70176","article-title":"Proteomic profiling of extracellular vesicles distinguishes prostate cancer molecular subtypes","volume":"14","author":"Ludwig","year":"2025","journal-title":"J. Extracell Vesicles"},{"key":"10.1016\/j.xcrm.2026.102764_bib57","doi-asserted-by":"crossref","DOI":"10.1093\/database\/baw030","article-title":"Genic insights from integrated human proteomics in GeneCards","volume":"2016","author":"Fishilevich","year":"2016","journal-title":"Database"},{"key":"10.1016\/j.xcrm.2026.102764_bib58","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102764_bib59","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126001813?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126001813?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T16:08:22Z","timestamp":1782490102000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379126001813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":59,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2666379126001813"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102764","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plasma extracellular vesicle proteomics nominates candidate biomarkers of 177Lu-PSMA-617 outcomes in metastatic prostate cancer patients","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102764","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102764"}}